Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
  Allergy & asthma
  Biotechnology
  Communicable diseases
  Drugs & drug processes
  Genetic engineering
  Genomics
  Health & ageing
  Health & poverty
  Health & special needs
  Health systems & management
  Major diseases
  Medical research
  Molecular biology
  Neuroscience
  Public health
  Rare & orphan diseases
  Other
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Indonesia
  Ireland
  Israel
  Italy
  Jamaica
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malaysia
  Malta
  Mexico
  Montenegro
  Morocco
  Mozambique
  Namibia
  Netherlands
  New Zealand
  Nigeria
  Norway
  Panama
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Sri Lanka
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Thailand
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States
  Vietnam


   Health & life sciences

Last Update: 04-02-2014  
Related category(ies):
Health & life sciences  |  Special Collections

 

Countries involved in the project described in the article:
Denmark  |  France  |  Germany  |  Ireland
Add to PDF "basket"

Anti-cancer drugs customised for children

One of the most common forms of cancer in children is acute lymphoblastic leukaemia, and the children affected have to rely on tablet-based treatments developed for adults. The European Union (EU)-funded LOULLA&PHILLA project designed a new range of anti-cancer drugs specifically aimed at children. The drugs ensure an appropriate safe dosage and are available in a flavoured oral liquid form to make it easier for parents to administer to children.

© fotolia

Behind the project was the Paris-based SME ‘Only for Children Pharmaceuticals’ O4CP which coordinated a team composed of highly qualified clinicians with expertise in drug development from the design stage to market.

“We recognised that there is a clear need for suitably customised medicines for children,” comments project coordinator Dr Vincent Grek of O4CP. “Children have different needs than adults and at a certain age might even require stronger doses than adults because they are capable of metabolising drugs faster,” he adds.

Over the course of the project the team succeeded in developing an oral liquid version of two medicines, namely mercaptopurine (6MP known as ‘Loulla’) and methotrexate (MTX known as ‘Philla’). These drugs are used for the ongoing treatment of childhood acute lymphoblastic leukaemia.

After successfully designing the new drugs with the support of the expertise of Prof Joërg Breitkreutz (Heinrich-Heine-Universität, Düsseldorf, Germany) and Dr Philippe Davioud (Laboratoires Philippe Davioud, France), the research team focused on demonstrating the stability of the various drug components and developing an innovative child-friendly system for administering the drug.

To cater for use with children and to make it easier for parents to administer, the researchers developed a system consisting of a two-part capsule with the active ingredient in a cap and a flavoured liquid at the bottom. Parents simply press the cap of the capsule and the active ingredient flows into the liquid where it then gets mixed. After a little shaking, parents use a syringe to obtain the prescribed dose. This innovative packaging called 'The Shaker' is now a patented technology.

“A special feature of our patented ‘Shaker’ system is that the design avoids the use of preservatives such as paraben and this in itself could have a major impact on drug formulation and product development for children,” says Dr Grek. “Our project aims to lead the development of new drugs for children and ultimately to provide them with the best medicines adapted to their tastes and medical needs,” he concludes.

Following clinical studies, the LOULLA&PHILLA team is now working to obtain marketing authorisations in various geographic regions and to make this new innovative formulation available to the children in need.

 

Project details

  • Project acronym: LOULLA&PHILLA
  • Participants: France (Coordinator), Ireland, Denmark, Germany
  • Project FP7 223401
  • Total costs: € 4 244 817
  • EU contribution: € 3 316 415
  • Duration: November 2008 - April 2012

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Project web site
Project information on CORDIS





  Top   Research Information Center